Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 1
2008 1
2009 2
2011 1
2012 1
2013 3
2014 7
2015 5
2016 3
2017 3
2018 5
2019 3
2020 6
2021 9
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber JS, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas H, Dalle S, Meyer N, Ascierto PA, Sandhu S, Eigentler T, Gutzmer R, Hassel JC, Robert C, Carlino MS, Di Giacomo AM, Butler MO, Muñoz-Couselo E, Brown MP, Rutkowski P, Haydon A, Grob JJ, Schachter J, Queirolo P, de la Cruz-Merino L, van der Westhuizen A, Menzies AM, Re S, Bas T, de Pril V, Braverman J, Tenney DJ, Tang H, Long GV. Weber JS, et al. Among authors: pigozzo j. J Clin Oncol. 2023 Jan 20;41(3):517-527. doi: 10.1200/JCO.22.00533. Epub 2022 Sep 26. J Clin Oncol. 2023. PMID: 36162037 Free PMC article. Clinical Trial.
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J. Lebbé C, et al. Among authors: pigozzo j. J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811280 Free PMC article. Clinical Trial.
Melanoma m1: diagnosis and therapy.
Rastrelli M, Tropea S, Pigozzo J, Bezzon E, Campana LG, Stramare R, Alaibac M, Rossi CR. Rastrelli M, et al. Among authors: pigozzo j. In Vivo. 2014 May-Jun;28(3):273-85. In Vivo. 2014. PMID: 24815827 Review.
Brain metastases from malignant melanoma.
Chiarion-Sileni V, Murr R, Pigozzo J, Sarti S, Tomassi O, Romanini A. Chiarion-Sileni V, et al. Among authors: pigozzo j. Forum (Genova). 2003;13(2):170-82; quiz 190. Forum (Genova). 2003. PMID: 14732883 Review.
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo AM, Ridolfi L, Tronconi MC, Trojaniello C, Bersanelli M, Garutti M, Indini A, De Risi I, De Tursi M, Merelli B, Morgese F, Occelli M, Cappellini GCA, Poletto S, Fedele D, Brugnara S, Frisinghelli M, Formisano L, Conca R, Tucci M, Russillo M, Ceroni L, Queirolo P, Targato G, Strippoli S, Mandalà M, Guida M, Quaglino P. Rubatto M, et al. Among authors: pigozzo j. Eur J Cancer. 2023 Jul;187:25-35. doi: 10.1016/j.ejca.2023.03.020. Epub 2023 Mar 23. Eur J Cancer. 2023. PMID: 37099946
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G, Fabricio ASC, Del Bianco P, Salizzato V, Favaretto A, Piccin L, Zustovich F, Fabozzi A, De Rossi C, Pigozzo J, De Nuzzo M, Cappelletto E, Bonanno L, Palleschi D, De Salvo GL, Guarneri V, Gion M, Chiarion-Sileni V. Pasello G, et al. Among authors: pigozzo j. J Transl Med. 2024 Mar 5;22(1):242. doi: 10.1186/s12967-024-04920-6. J Transl Med. 2024. PMID: 38443899 Free PMC article.
The immune cell landscape of metastatic uveal melanoma correlates with overall survival.
Tosi A, Cappellesso R, Dei Tos AP, Rossi V, Aliberti C, Pigozzo J, Fabozzi A, Sbaraglia M, Blandamura S, Del Bianco P, Chiarion-Sileni V, Rosato A. Tosi A, et al. Among authors: pigozzo j. J Exp Clin Cancer Res. 2021 May 4;40(1):154. doi: 10.1186/s13046-021-01947-1. J Exp Clin Cancer Res. 2021. PMID: 33947438 Free PMC article.
Per- and polyfluoroalkyl substances (PFAS) exposure in melanoma patients: a retrospective study on prognosis and histological features.
Del Fiore P, Cavallin F, Mazza M, Benna C, Monico AD, Tadiotto G, Russo I, Ferrazzi B, Tropea S, Buja A, Cozzolino C, Cappellesso R, Nicolè L, Piccin L, Pigozzo J, Chiarion-Sileni V, Vecchiato A, Menin C, Bassetto F, Dei Tos AP, Alaibac M, Mocellin S. Del Fiore P, et al. Among authors: pigozzo j. Environ Health. 2022 Dec 9;21(1):126. doi: 10.1186/s12940-022-00944-x. Environ Health. 2022. PMID: 36482443 Free PMC article.
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
Guida M, Bartolomeo N, Quaresmini D, Quaglino P, Madonna G, Pigozzo J, Di Giacomo AM, Minisini AM, Tucci M, Spagnolo F, Occelli M, Ridolfi L, Queirolo P, De Risi I, Valente M, Sciacovelli AM, Chiarion Sileni V, Ascierto PA, Stigliano L, Strippoli S. Guida M, et al. Among authors: pigozzo j. J Transl Med. 2022 Apr 5;20(1):159. doi: 10.1186/s12967-022-03359-x. J Transl Med. 2022. PMID: 35382857 Free PMC article.
52 results